Research Articles

Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.

stats1
stats2
stats3
stats4

Search for:

     Sulfonylurea
31 records.
Article ID PMID Source Title Publish Year
A00255 35163991 Molecules Sitagliptin Is More Effective Than Gliclazide in Preventing  Pro-Fibrotic and Pro-Inflammatory Changes in a Rodent Model of Diet-Induced Non-Alcoholic Fatty Liver Disease. 2022 Details
A01347 34779535 Hepatology Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. 2021 Details
A01811 34606980 Endocr Pract Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. 2021 Details
A02366 34401141 Ann Med Surg (Lond) Prevalence of fatty liver disease and its associated factors among Jordanian patients with type 2 diabetes mellitus: A cross-sectional study. 2021 Details
A03104 34129693 Hepatology Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. 2021 Details
A04814 33497019 Liver Int Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. 2021 Details
A05041 33397230 Curr Pharm Des Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease. 2021 Details
A06074 33015726 Curr Diab Rep Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. 2020 Details
A07866 32329963 J Diabetes Investig Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study. 2020 Details
A08201 32207583 Adv Clin Exp Med Advanced glycation end products derived from serum albumin modification by glucose (AGE-1) reflect clustering of lipid-associated metabolic abnormalities and are decreased in patients treated with acarbose: A cross-sectional study. 2020 Details
A08867 31956961 Diabetes Ther Study Protocol for Pleiotropic Effects and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. 2020 Details
A10550 31292843 Clin J Gastroenterol Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. 2019 Details
A11204 31000862 J Pak Med Assoc Expert Opinion: Use of sodium glucose co-transporter type-2 inhibitors in South Asian population -The Pakistan perspective. 2019 Details
A11769 30758417 Rev Assoc Med Bras (1992) The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data. 2019 Details
A12660 30341231 Postgrad Med J Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. 2018 Details
A13245 30066148 Diabetologia Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial. 2018 Details
A16488 28358980 Cochrane Database Syst Rev Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. 2017 Details
A16925 28089623 Dig Liver Dis Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? 2016 Details
A18464 27110380 BMJ Open Gastroenterol Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. 2016 Details
A22315 24669954 Expert Opin Drug Metab Toxicol Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. 2014 Details
A23356 23845075 Curr Diabetes Rev The influence of diabetes in the pathogenesis and the clinical course of hepatocellular carcinoma: recent findings and new perspectives. 2013 Details
A24422 22913901 Postgrad Med Managing diabetes in patients with chronic liver disease. 2012 Details
A24577 22734967 Clin Sci (Lond) Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis. 2012 Details
A28077 16503761 Expert Opin Investig Drugs Recent findings concerning thiazolidinediones in the treatment of diabetes. 2006 Details
A31877 29656603 Pest Manag Sci Improvement and application of the PCPF-1@SWAT2012 model for predicting pesticide transport: a case study of the Sakura River watershed. 2018 Details
A37472 15605307 Semin Liver Dis Hepatotoxicity of drugs used for treatment of obesity and its comorbidities. 2004 Details
A44501 28459036 Indian J Endocrinol Metab Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. 2020 Details
A47050 27861855 Int J Cancer Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. 2016 Details
A47858 30742277 Drugs The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. 2019 Details
A51686 34920733 Cardiovasc Diabetol Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. 2021 Details
A52934 19349323 Circulation Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. 2009 Details